(Q37087142)

18 August 2017

1 reference

title

Paliperidone for schizophrenia (English)

1 reference

18 August 2017

0 references

Christian Dolder

1

1 reference

PubMed ID

18281731

18 August 2017

Michael Nelson

series ordinal

2

1 reference

PubMed ID

18281731

18 August 2017

Zachariah Deyo

series ordinal

3

1 reference

18 August 2017

1 March 2008

1 reference

American Journal of Health-System Pharmacy

18 August 2017

1 reference

18 August 2017

65

1 reference

18 August 2017

5

1 reference

18 August 2017

403-413

1 reference

The Economic Burden of Schizophrenia in the United States in 2002

18 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Impact of substance use disorder on ADHD and its treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

31 March 2020

Paliperidone: quo vadis?

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Plasma protein binding of risperidone and its distribution in blood

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Targeting the dopamine D2 receptor in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

EPS profiles: the atypical antipsychotics are not all the same

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Pharmacogenetics, drug-metabolizing enzymes, and clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070261

31 March 2020

Identifiers

DOI

10.2146/AJHP070261

1 reference

18 August 2017

1 reference

PubMed ID

18281731